Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1
NCT05660980Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of cabotegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2024; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05660980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660980.